Disease · MONDO_0018469
pulmonary non-tuberculous mycobacterial infection
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. pulmonary non-tuberculous mycobacterial infection. Diseases, record MONDO_0018469. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018469
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Nontuberculous Mycobacterial Lung Disease, non-tuberculous mycobacterial lung disease
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AMIKACIN | CHEMBL177 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| EPETRABOROLE | CHEMBL3549142 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INTERLEUKIN-7 | CHEMBL4297772 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| AZITHROMYCIN | CHEMBL529 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETHAMBUTOL | CHEMBL44884 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIFAMPIN | CHEMBL374478 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01315236 | Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria | Phase 2 | 90 | 2019-08-21 | Mycobacterium Infections, Nontuberculous | AMIKACIN | Its record names the disease | ClinicalTrials.gov |
| NCT02372383 | Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis | Not applicable | 31 | 2021-02-11 | Cystic Fibrosis | AZITHROMYCIN, ETHAMBUTOL, RIFAMPIN | Its record names the disease | ClinicalTrials.gov |
| NCT07301320 | Epetraborole in Patients With Mycobacterium Abscessus Lung Disease | Phase 2 | 84 | Mycobacterium Abscessus Infection | EPETRABOROLE | Its record names the disease | ClinicalTrials.gov | |
| NCT04154826 | Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease | Phase 2 | 8 | Mycobacterium Infections, Nontuberculous | INTERLEUKIN-7 | Its record names the disease | ClinicalTrials.gov | |
| NCT01528930 | Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease | Phase 2 | 0 | Pulmonary Non-tuberculous Mycobacterial Lung Disease | AMIKACIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| LAI 590 mg QD vs Placebo: Number of Subjects With Negative NTM Culture for the LAI Arm at Day 84 Compared to the Placebo Arm at Day 84 | 14 of 44 | 4 of 45 | 89 | NCT01315236 | Trial comparisons |
| LAI 590 mg QD vs Placebo: Number of Participants Requiring Rescue Anti-mycobacterial or Other Rescue Drugs During the 84-day Double-blind Phase | 21 of 44 | 11 of 45 | 89 | NCT01315236 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018469
GET https://conductscience.org/api/diseases/v1/MONDO_0018469/drugs